NASDAQ:ODTX Odyssey Therapeutics (ODTX) Stock Price, News & Analysis $23.64 -0.87 (-3.55%) As of 09/10/2026 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsInsider TradesNews and TrendsOwnershipSEC FilingsShort Interest About Odyssey Therapeutics Stock (NASDAQ:ODTX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Odyssey Therapeutics alerts:Sign Up Key Stats Today's Range$23.50▼$25.3850-Day Range$15.56▼$28.7652-Week Range$15.10▼$29.05Volume192,715 shsAverage Volume168,401 shsMarket Capitalization$1.14 billionP/E RatioN/ADividend YieldN/APrice Target$35.75Consensus RatingModerate Buy Company Overview Odyssey Therapeutics Inc. is a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines which are designed to precisely target disease pathology. Odyssey Therapeutics Inc. is based in BOSTON. Read More Odyssey Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks69th Percentile Overall ScoreODTX MarketRank™: Odyssey Therapeutics scored higher than 69% of companies evaluated by MarketBeat, and ranked 434th out of 907 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.1 / 5Analyst RatingModerate Buy Consensus RatingOdyssey Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.63, and is based on no strong buy ratings, 6 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialOdyssey Therapeutics has a consensus price target of $35.75, representing about 51.2% upside from its current price of $23.64.Amount of Analyst CoverageOdyssey Therapeutics has only been the subject of 4 research reports in the past 90 days.Read more about Odyssey Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Odyssey Therapeutics are expected to grow in the coming year, from ($5.99) to ($4.98) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Odyssey Therapeutics is -3.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Odyssey Therapeutics is -3.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted4.60% of the float of Odyssey Therapeutics has been sold short.Short Interest Ratio / Days to CoverOdyssey Therapeutics has a short interest ratio ("days to cover") of 12.81, which indicates bearish sentiment.Change versus previous monthShort interest in Odyssey Therapeutics has recently decreased by 1.80%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldOdyssey Therapeutics does not currently pay a dividend.Dividend GrowthOdyssey Therapeutics does not have a long track record of dividend growth. News and Social Media3.4 / 5News Sentiment1.45 News SentimentOdyssey Therapeutics has a news sentiment score of 1.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.86 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Odyssey Therapeutics this week, compared to 3 articles on an average week.Search InterestOnly 1 people have searched for ODTX on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows1 people have added Odyssey Therapeutics to their MarketBeat watchlist in the last 30 days. Company OwnershipN/AInsider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Odyssey Therapeutics insiders have not sold or bought any company stock.Percentage Held by InstitutionsOdyssey Therapeutics has minimal institutional ownership at this time.Read more about Odyssey Therapeutics' insider trading history. Receive ODTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Odyssey Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ODTX Stock News HeadlinesWhat is HC Wainwright's Estimate for ODTX Q3 Earnings?August 31, 2026 | americanbankingnews.comOdyssey Therapeutics to Participate in Upcoming Investor ConferencesAugust 26, 2026 | globenewswire.comSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from collapsing — and billionaire Sam Altman is now an investor. This under-the-radar firm is drawing serious attention from those watching the energy infrastructure space closely. | Altimetry (Ad)Odyssey Therapeutics Inc.August 18, 2026 | marketwatch.comOdyssey Therapeutics: Q2 Earnings SnapshotAugust 6, 2026 | chron.comEvotec and Odyssey Therapeutics Enter AI-Enabled R&D Collaboration in Autoimmune and Inflammatory DiseasesAugust 6, 2026 | prnewswire.comOdyssey Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate UpdateAugust 4, 2026 | globenewswire.comOdyssey Therapeutics Stock Price HistoryJuly 16, 2026 | investing.comSee More Headlines ODTX Stock Analysis - Frequently Asked Questions How have ODTX shares performed this year? Odyssey Therapeutics' stock was trading at $17.45 on May 11, 2026. Since then, ODTX shares have increased by 35.5% and is now trading at $23.64. How were Odyssey Therapeutics' earnings last quarter? Odyssey Therapeutics, Inc. (NASDAQ:ODTX) announced its quarterly earnings data on Wednesday, August, 5th. The company reported ($1.74) EPS for the quarter. When did Odyssey Therapeutics IPO? Odyssey Therapeutics (ODTX) raised $264 million in an initial public offering (IPO) on Friday, May 8th 2026. The company issued 15,500,000 shares at a price of $16.00-$18.00 per share. When does the company's lock-up period expire? Odyssey Therapeutics's lock-up period expires on Wednesday, November 4th. Odyssey Therapeutics had issued 15,500,000 shares in its initial public offering on May 8th. The total size of the offering was $279,000,000 based on an initial share price of $18.00. After the expiration of the company's lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company will be lifted. Who are Odyssey Therapeutics' major shareholders? Top institutional shareholders of Odyssey Therapeutics include Citadel Advisors LLC (0.46%) and The Manufacturers Life Insurance Company (0.07%). Insiders that own company stock include Tpg Gp A, Llc, Dimension Capital Ii, LP, Nan (Ln) Li, Sr One Capital Management, Llc, Jeffrey M Leiden, Jason Haas and Shelley Chu. View institutional ownership trends. How do I buy shares of Odyssey Therapeutics? Shares of ODTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings8/05/2026Today9/11/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:ODTX CIK1882782 Webodysseytx.com Phone617-865-9628FaxN/AEmployeesN/AYear FoundedN/APrice Target and Rating Average Price Target for Odyssey Therapeutics$35.75 High Price Target$44.00 Low Price Target$29.00 Potential Upside/Downside+51.2%Consensus RatingModerate Buy Rating Score (0-4)2.63 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio11.36 Quick Ratio11.36 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares48,060,000Free FloatN/AMarket Cap$1.14 billion OptionableN/A BetaN/A 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (NASDAQ:ODTX) was last updated on 9/11/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Odyssey Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Odyssey Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
